Therapeutic Potential of Human Adipose Stem Cells in a Rat Myocardial Infarction Model by Hwangbo, Seal et al.
Yonsei Med J   http://www.eymj.org    Volume 51   Number 1   January 2010 69
Myocardial infarction is the leading cause of morbidity and mortality in industrialized
countries. The critical prognosis factor of myocardial infarction is the size of the
myocardial infarction, which is directly correlated with heart dilation and cardiac
failure. Despite current pharmacotherapy, interventional procedures and surgical
therapeutic methods preventing ventricular remodeling is limited due to their
inability to repair damaged myocardium. Recent animal and clinical studies show
that various types of stem cells can decrease cardiac infarction size and improve
cardiac function .
1-4
Previous studies have focused on the use of embryonic stem cells, cord blood
derived stem cells, and skeletal muscle myoblasts. However, the clinical use of
these cells has presented problems, including low cell number upon harvest and
an ethical controversy. 
Mesenchymal stem cells (MSCs) from adult tissues provide an attractive and
alternative source of cells for tissue engineering. In addition, adult MSCs are
relatively easily harvested from bone marrow, skin, muscle and adipose tissue.
5-7
Currently, bone marrow is the primary source of adult mesenchymal stem cells.
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Purpose: Stem cell transplantation is expected to have good effects in the treatment of myocardial infarction (MI).
We tested the effect of the transplantation of human adipose-derived cells (ASCs) in Sprague-Dawley (SD) rats
with myocardial infarctions. Materials and Methods: ASCs were isolated from the waste of elective abdominal
surgery. The MI model was set up in SD rats by permanent ligation of the left anterior descending coronary artery.
One week after MI, either 1 x 10
6 ASCs or an equal volume of phosphate-buffered saline (PBS) was injected into
the infarct zone. Cardiac function was assessed by echocardiography, 1 day, 1 week, 2 weeks, and 4 weeks after
treatment. Four weeks after transplantation, immunohistochemistry was performed. Results: Left ventricular
function, including fractional shortening (FS), and ejection fraction (EF) showed a significant improvement in the
ASCs transplantation group compared to the PBS group 4 weeks after treatment (p < 0.05). The anterior wall
thickness of the left ventricle was significantly thicker in the ASCs transplantation group compared to the PBS
group (p < 0.01). Multiple troponin T staining, and irregular, small amounts of connexin 43 expression also was
observed in the ASCs transplantation group. Infarcted myocardium showed higher capillary density in the ASCs
transplantation group than in the PBS injected group (p < 0.01). Conclusion: This study provides encouraging
evidence that transplantation of ASCs can improve cardiac function of infarct myocardium in rat models with a
limitation of cardiac remodeling, improved wall thickness, and increased neovascularization.
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However, the low number of cells necessitates in vitro
culture expansion to obtain sufficient numbers of cells for
clinical applications.
8 In addition, bone marrow stem cells
are not readily available for the immediate treatment of
acute myocardial infarction. 
Mesenchymal stem cells derived from adipose tissue,
adipose-derived stem cells (ASCs), were first identified by
Zuk, et al.
9 as a source of adult mesenchymal stem cells.
After lineage-specific stimulation, ASCs show multiple-
lineage differentiation potentials. They can differentiate
into adipogenic, chondrogenic, myogenic, cardiomyogenic,
osteogenic, endothelial, and neurogenic lineages.
10,11
Adipose tissue is an abundant, expandable, and easily
accessible source of mesenchymal stem cells. In our labo-
ratory, we have established a method that readily isolates
and expands stem cells from human adipose tissue. The
purpose of this study is to investigate whether transplanta-
tion of ASCs could improve cardiac function in a rat myo-
cardial infarction model. 
ASCs preparation and labeling
We used human waste adipose tissues which were obtain-
ed after elective surgery and donated upon informed consent
of the patients from our hospital. 
The isolation of cells was performed as described prev-
iously by Zuk, et al.
12 In brief, adipose tissue was stored in
sterile phosphate-buffered saline (PBS) at 4˚C. Then, the
tissue was washed extensively with PBS and mechanically
chopped before processing. To isolate the stromal vascular
fraction (SVF), the tissue was enzymatically digested with
PBS containing 0.1% collagenase A (Sigma Aldrich, St.
Louis, MO, USA) for 30 to 60 minutes at 37˚C with inter-
mittent shaking. 
The digested tissue was then washed with Dulbecco’s
modified Eagles medium (DMEM) (Sigma Aldrich, St.
Louis, MO, USA) containing 10% fetal bovine serum
(FBS), following centrifugation for 10 min at 200 g to
remove mature adipocytes. The cell pellet was resuspensed
in PBS and passed through a 100-µm mesh (BD, Falcon,
Franklin Lakes, NJ, USA) to remove suspension. 
Cells from the SVF were seeded and cultured for several
passages in DMEM supplemented with 10% FBS, 100
U/mi penicillin, 100 µg/mL streptomycin in a 37˚C incubator
with 5% CO2. Cells reaching 90% confluency were deta-
ched with 0.5 mM ethylenediaminetetraacetic acid (EDTA)
/0.05% trypsin for 10 min at 37˚C and then replated. Pas-
sages p3 through p5 were used for all in vivo experiments.
Cell viability was assessed using the trypan blue exclusion
assay with 0.2% trypan blue. 
In culture, ASCs express cell-surface markers similar to
those expressed by bone marrow MSCs, including CD117
(stem cell factor receptor), CD29 (β1-intergrin), CD 105
(mutilineage differentiation markers), CD-90, CD54 [inter-
cellular adhesion molecule-I (ICAM-I)] and CD44. 
5,7
In addition, ASCs, like bone marrow MSCs, do not
express the endothelial marker CD31, or the hematopoietic
marker CD45. There is some controversy in the literature
regarding the expression of CD34 that is widely used as a
marker of hematopoietic stem cells but is also highly ex-
pressed in vascular endothelial cell.
13,14 Using flow cytome-
tric analysis, we analyzed several stem cell markers on
ADCs including CD34, CD44, CD29, and CD45. HLA
DR and c-kit (all, BD PharMingen, San Diego, CA, USA)
expressions were also observed. 
One day before cell transplantation, ASCs were labeled
with 4,6-diamidino-2-phenylindole (DAPI) (Sigma Aldrich,
St. Louis, MO, USA) for 12 hours in the ASC transplan-
tation group. 
Myocardial infarction model and stem cell 
transplantation
All animal studies were performed in accordance with the
Animal Studies Committee guidelines, The Catholic Univer-
sity of Korea, Korea.
Male Sprague-Dawley (SD) rats weighing 230-260 g at
the beginning of the study were used. SD rats were anes-
thetized with ketamine (80 mg/kg, intraperitoneally) and
xylazine (8 mg/kg, intraperitoneally) and were placed in a
supine position with all four paws taped. Tracheostomy
and mechanical ventilation was maintained with room air
by using a small animal ventilator (Harvard Apparatus,
Holliston, MA, USA) and a 20-guage IV catheter as the
tracheostomy tube throughout the procedure. A thoraco-
tomy was performed through the fifth intercostal space and
ribs were retracted. After opening the pericardium, the left
anterior descending artery of heart (LAD) was permanently
ligated with a 7-0 polypropylene suture 5 mm from the left
atrial appendage. Infarction of the anterior wall of the left
ventricle was confirmed by the presence of a pale myocar-
dium after LAD ligation. The chest wall, muscle layers
and skin were then closed with 4-0 silk sutures in three
layers. The tracheostomy tube was removed and the suture
of the tracheostomy site with 7-0 polypropylene was done. 
Three or four days later, surviving rats with fractional
shortening less than 40% were included in this study. One
week after myocardial infarction, 30 rats were divided
randomly into two groups: the ASCs transplantation group
(n = 17, group 1) and the PBS injection control group (n =
13, group 2). The rats were anesthetized and ventilated as
described above. Their chest was opened and ASCs (1×
10
6 cells) in 40 µL medium or same volume of PBS were
MATERIALS AND METHODSinjected in the margin and in the center of infarction with
four separate injections using a 30-guage needle.
The sham operation group (n = 10, group 3) underwent
thoracotomy and cardiac exposure with neither coronary
artery ligation nor cell transplantation.
Echocardiographic analysis
Echocardiography was performed 1 day, 1 week, 2
weeks and 4 weeks after cell transplantation in all 3 groups.
Rats were anesthetized with ketamine (50 mg/kg, intraperi-
toneally) and xylazine (5 mg/kg, intraperitoneally). Echocar-
diography was performed with a commercially available
echocardiography system (IU22, Philips, Bothell, MA,
USA) with 17-5 MHz small linear array transducer (hockey
stick). 
All measurements were taken over 2 consecutive cardiac
cycles and averaged. All measurements were performed
by an experienced cardiologist who was blind to the study
group. Left ventricular end systolic diameter (LVESD),
left ventricular end diastolic diameter (LVEDD), and left
ventricular anterior wall thickening at the end-diastole data
were obtained by a two dimensional targeted M-mode
view. The percentage of fractional shortening (FS) was
computed as representative of systolic function: FS(%) =
(LVEDD-LVESD) / LVEDD ×100. Ejection fraction (EF)
was calculated as: EF(%) = (Voldia - Volsys) / Voldia. End-
diastolic volumes (Voldia) and end-systolic volumes (Volsys)
were calculated by manually drawing endocardial contours
at end-diastolic and end-systolic phases in the apical two
chamber view using the modified Simpson’s rule.
15
Histology and immunohistochemistry
Four weeks after cell transplantation, all rats underwent the
final echocardiography and were then sacrificed with an
overdose of ketamine and xylazine. The hearts were remov-
ed and fixed with 4% phosphate-buffered formalin solution.
The following day, the hearts were sectioned into two parts
from mid-ventricular level to apex and then embedded in
paraffin. Paraffin sections (4 µm thickness) were mounted
on coated slides were dried, deparaffinized, rehydrated and
stained with hematoxylin-and-eosin staining for an evalua-
tion of morphology. Sections were then used to identify
the transplanted ASCs labeled with DAPI by fluorescent
microscopy. One of the adjacent the ASCs positive sections
preceded immunohistochemical stainings. Representative
paraffin-embedded sections were immunostained with
anti-α-smooth muscle actin (1 : 400, Chemicon, Temecula,
CA, USA), anti-troponin T (Sigma Chemical, St. Louis,
MO, USA), anti-connexin-43 (Invitrogen) and anti-collagen
I (Santa Cruz Biotechnology, Santa Cruz, CA, USA). 
Blood vessel density was measured at 400× magnifica-
tion in three microscopic fields after immunostaining with
anti-α-smooth muscle actin (1 : 400, Chemicon, Temecula,
CA, USA).  
Statistical analysis
Results are reported as mean ± standard deviation. Statisti-
cal analysis was performed with the SPSS program package
(SPSS version 12.0; SPSS, Chicago, IL, USA). Differences
between the two groups were compared with the Student’s
t-test. Groups were compared with one-way analysis of
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Fig. 1. Flow-cytometric analysis of adult adipose cells expanded to three passages. Most of the ASCs expressed CD44 and CD29, and did not express for CD34, CD45,
HLADR and c-kit. ASCs, adipose-derived cells.variance (ANOVA) test. A value of p < 0.05 was consi-
dered statistically significant.  
Characterization of ASCs
CD44 and CD29 expressions were observed in 92% and
90%, respectively. CD45, HLA DR and c-kit expressions
were observed in less than 1% (Fig. 1). CD34 was expressed
in  8.3 % in our study. 
Assessment of echocardiographic evaluation
Table 1 shows the results of echocardiographic function in
three groups. Left ventricular function, including fractional
shortening (FS) and ejection fraction (EF) at 1 day, 1 week,
and 2 weeks after treatment, did not differ between group 1
and group 2. However, results after 4 weeks showed a
significant improvement of cardiac function in group 1
compared to group 2 (Fig. 2). The FS was 30.3 5 ± 4.2%
in group 1 and 24.15 ± 5.8% in group 2 and the EF was
57.75 ± 8.0% in group 1 and 45.75 ± 9.3% in group 2 four
weeks after treatment (p < 0.05). However, EF and FS in
group 1 were lower than in group 3, which suggests that
group 1 did not recover normal function fully.
The anterior wall thickness was significantly thicker in
group 1 than in group 2 four weeks of treatment (1.55 ±
0.4 mm and 1.25 ± 0.2 mm, respectively) (p< 0.01).
Myocyte differentiation of human ASCs
To identify human ASCs in vivo, DAPI labeled ASCs
were observed at the transplant area. DAPI labeled ASCs
were expressed in the rat heart 4 weeks after cell treatment.
DAPI labeled ASCs were observed near the infracted
myocardium, but development into the  multinucleated cell
was not observed in our study. However, troponin T staining
was observed near the cell transplantation area but not at
the PBS injection area (Fig. 3). Troponin T is the early
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Table 1.Echocardiographic Data
Timepoint parameter Sham (group 3) PBS (group 2) ASCs (group 1)
1 day, n value 10 11 16
IVSd (mm) 1.6 ± 0.2 1.4 ± 0.2 1.3 ± 0.3
LVESD (mm) 5.7 ± 0.5 8.3 ± 1.2 7.6 ± 0.9
LVEDD (mm) 3.2 ± 0.4 6.6 ± 1.3 6.0 ± 0.9
FS (%) 43.3 ± 3.4 21.2 ± 5.3 21.8 ± 6.4
EF (%) 73.8 ± 3.9 40.8 ± 9.4 42.6 ± 11.1
1 wk, n value 10 11 16
IVSd (mm) 1.6 ± 0.9 1.1 ± 0.3 1.1 ± 0.1
LVESD (mm) 6.0 ± 0.5 7.1 ± 1.2 7.9 ± 2.2
LVEDD (mm) 3.5 ± 0.5 5.9 ± 1.0 6.5 ± 1.7
FS (%) 41.5 ± 5.6 17.6 ± 3.0 16.4 ± 5.0
EF (%) 71.2 ± 6.7 35.5 ± 5.5 33.1 ± 9.3
2 wks, n value 10 10 14
IVSd (mm) 1.5 ± 0.1 1.4 ± 0.3 1.2 ± 0.3
LVESD (mm) 6.2 ± 0.4 8.3 ± 0.8 7.4 ± 0.7
LVEDD (mm) 3.9 ± 0.5 6.5 ± 0.9 5.6 ± 0.8
FS (%) 36.9 ± 7.1 21.4 ± 7.5 24.6 ± 6.0
EF (%) 65.2 ± 9.6 41.2 ± 12.3 46.7 ± 9.7
4 wks, n value 10 10 14
IVSd (mm) 1.6 ± 0.1 1.2 ± 0.2 1.5 ± 0.4*
LVESD (mm) 6.3 ± 0.4 8.1 ± 0.9 7.0 ± 1.1
�
LVEDD (mm) 3.9 ± 0.5 6.2 ± 1.1 5.0 ± 1.3
�
FS (%) 36.7 ± 6.9 24.1 ± 5.8 30.3 ± 4.2
�
EF (%) 66.3 ± 8.3 45.7 ± 9.3 57.7 ± 8.0
�
IVSd, interventricular septal thickness at end-diastolic; LVESD, left ventricular end-systolic dimension; LVEDD, left ventricular end-diastolic 
dimension; FS, fractional shortening; EF, ejection fraction; PBS, phosphate-buffered saline.
*p< 0.01 vs. PBS (group 2).
�p< 0.05 vs. PBS (group 2).
RESULTSmarker of myocyst.
Group 3 showed parallel alignment of cardiomyocysts
with regular expression of connexin 43. However, group 1
showed irregular expression and small amounts of connexin
43 and group 2 showed little expression of connexin 43
(Fig. 3). 
Assessment of neovascularization 
Capillary density increased more in group 1 and group 2,
than in group 3, as determined by α-smooth muscle actin
immunostaining (Fig. 3).
The vascular densities were in 2.2 ± 0.3 vessels/mm
2,
3.5  ± 0.4 vessels/mm
2, and 6.8 ± 1.3 vessels/mm
2 in group
3, 2, and 1, respectively.
Assessment of collagen expression
In group 1 and group 2, collagen volume increased marke-
dly, compared to group 3. In group 1, less increased colla-
gen volume was observed than in group 2. Group 3 showed
scanty and uniformly distributed collagen, while group 1
showed clumpy distribution.
Various cell types are currently under investigation for their
therapeutic potential in cardiac infarction. Several clinical
trials have reported encouraging results with stem cell
transplantation to myocardial infarction patients.
16,17
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DISCUSSION
Fig. 2. Echocardiographic images after treatment. M-mode echocardiographic
images demonstrating an increase in anterior wall thickening in the left ventricle
and an improvement of ventricular function in the ASC transplantation group at
the top images. Similar images representing post-infarction remodeling with left
ventricular dilatation of the PBS group in middle. Echocardiographic images in
the control sham operation group at the bottom. ASCs, adipose-derived cells;
PBS, phosphate-buffered saline.











Fig. 3.H & E staining (A,×400) and immunohistochemical staining of connexin 43 (B,×100), troponin T (C,×100) and α-smooth muscle actin (D,×100) of the three groups.
ASCs, adipose-derived cells; PBS, phosphate-buffered saline.










mHaving an optimal source of cells to be transplanted is
important and human adult stem cells are an attractive
source. Bone marrow stem cells have been used in hema-
tological disorders and were studied in cardiac infarction
models. However, findings of these studies are controversial
and no definite conclusion can be drawn from them.
18-20 In
addition, obtaining the therapeutic quantity of these cells
requires general anesthesia and hospitalization. A study
using autologous skeletal myocytes showed clear benefit,
but also showed concerns of arrhythmia.
21-23
Brown adipose tissue also expresses stem cell markers of
cardiomyocytes and differentiates into cardiomyocytes.
24
Brown adipose tissue is uncommon in adults and using
brown adipose tissue in cell transplantation has limitations. 
Adult human adipose stem cell (ASC) is likely a feasible
source of stem cells because it is abundant, it lacks donor
limitation and obtaining it has a low risk of side effects.
After lineage-specific stimulation, ASCs show multiple-
lineage differentiation including adipogenic, chondrogenic,
myogenic, cardiomyogenic, osteogenic, endothelial and
neurogenic lineages, similar to bone marrow stem cells.
10,11
Transplantation of these cells can decrease the size of a
myocardial infarction by promoting angiogenesis and
myogenesis.
25-28 
Our echocardiography results revealed better heart func-
tion in the ASCs transplantation group than in the PBS
injection group. By the fourth week after PBS injection,
definite left ventricular functional improvement was not
observed and dilatation of the left ventricle without wall
thickening in the infracted area continued. In contrast, the
ASC transplantation group showed improvement of left
ventricular function 4 weeks after transplantation with
abundant neovascularization. Neovascularization in the
infracted areas is an important component in the cardiac
remodeling process.
14,29 Miranville, et al.
30 showed that ASCs
with CD34+/CD31- are capable of in vivo and in vitro endo-
thelial differentiation. Mirencille, et al.
30 also showed that
delivery of ACSs accelerates perfusion in the limb ischemic
model. Rehman, et al.
31 suggested that improvement of
perfusion in the ischemic region was due to the vascular
endothelial growth factor (VEGF) and other angiogenic
factors expressed by ASCs. In the present study, DAPI
labeled ASCs were observed near and in the arterioles walls
of the infarct myocardial area. This strongly suggests that
ADCs have the ability to differentiate into endothelial cells,
and thus play a potential role in neovascularization. Al-
though the precise mechanism by which ASCs transplan-
tation limits the myocardial remodeling is unknown, ASCs
can improve tissue ischemia in part through paracrine
mechanisms.
Planat-Bérnaed, et al.
32 observed spontaneous differen-
tiation of rat ASCs into cardic myocytes after three weeks of
culture in methycellulose-based culture media.
30 In this
study, the ASC transplantation group expressed large
quantities of troponin I, the cardiac transcription factor and
expressed small quantities of connexin 43, a gap junction
protein, at contact points with native cardiac myocytes and
with ASCs in cell transplantation areas. These results are
consistent with an in vivo study of differentiation of ASCs
into cardiomyocysts.
33 However, we were not able to ob-
serve direct transformation of the DAPI labeled ASCs into
multinucleated cells or myocysts.
The most striking observation in this study is the increase
in the anterior wall thickness of the left ventricle in the ASC
transplantation group. The maintenance of the thickness of
infarcted myocardium may be due to the alteration of colla-
genase activity or to other enzymatic pathways responsible
for cardiac remodeling and fibrosis. Collagen composes
most of the extracellular matrix in infarcted myocardium.
Because the loss of cardiomyocytes and the replacement of
collagen are responsible for ventricular remodeling after
myocardial infarction, preventing cell apoptosis and fibrosis
is a major mechanism of cell therapy in the cardiac infarc-
tion model. Our results demonstrated a lack of collagen
replacement in the cell transplantation group compared to
the PBS injection group. 
In this study, we observed three cases which represent
multifocal intramyocardial calcifications in the ASC trans-
plantation site. These results demonstrate that direct trans-
plantation of unselected stem cells into infarcted myocar-
dium may induce intramyocardial calcification.
34 We spec-
ulated that unselected ASCs contained other progenitor cells
that might differentiate into bone or cartilage creating an
island of calcification. ASCs cultured in a specific culture
medium would differentiate into myocytes more efficiently
in cell transplantation.
In this study, we delivered cells 1 week after myocardial
infarction to avoid cell loss due to inflammation and wash-
out at the infarct area.
35-37 Existing techniques for tracking
stem cells include fluorescent transfection, transfection of
fluorescence in situ hybridization, using specific surface
markers of transplanted cells and labeling cells with iron-
oxide nanoparticles or radiotracers.
38-40 In this study, we used
commercially available fluorescent dyes to label cell nuclei
(DAPI). This dye was easy to handle and resulted in a 100%
labeling of cells. However this agent intercalates into DNA
and may interfere with normal cell function, one of the limi-
tations of our study. Several other limitations in our study
were also revealed. The number of animals in each group
was relatively small. Echocardiography to evaluate heart
function is controversial in small animal assessment due to
operator dependant procedures.
In conclusion, the present study provides encouraging
evidence that transplantation of ASCs can improve cardiac
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cardiac remodeling, improved wall thickness and increased
neovascularization results in improved cardiac function.
Many issues must be explored before the safe application of
these cells in the clinical setting. However, with appropriate
validation of cell types and optimal performance, they
should achieve a demonstrable benefit in cell therapy.
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